沙美特罗替卡松干粉剂吸入对支气管哮喘患者肺功能的影响  

Effect of salmeterol and fluticasone propionate dry powder inhalant on the lung function and quality of life in patients with bronchial asthma

作　　者：梁刚[1] 刘剑文 陈峙余[1] 何建猷[3] 

机构地区：[1]湛江中心人民医院呼吸内科,广东省湛江市524037 [2]湛江市医学临床研究所,广东省湛江市524037 [3]广东医学院附属医院呼吸内科,广东省湛江市524001

出　　处：《中国临床康复》2005年第11期24-25,共2页Chinese Journal of Clinical Rehabilitation

摘　　要：目的:观察沙美特罗替卡松干粉剂吸入干预支气管哮喘的效果,探讨其对患者肺功能和生活质量的影响。方法:选择2002-06/2004-04湛江中心人民医院院呼吸内科门诊符合纳入标准的中、重度支气管哮喘患者64例为研究对象。随机将患者分为治疗组和对照组,每组32例。治疗组每日吸入沙美特罗替卡松干粉剂2次,共24周;对照组每日吸入替卡松气雾剂2次,共24周。治疗前及治疗第1,4,12,24周检查肺功能和治疗前后进行生活质量评估比较。结果:治疗组治疗后第1周哮喘症状日间评分、夜间评分和沙丁胺醇气雾剂用量犤(1.69±0.14)分,(1.15±0.15)分,(2.23±0.23)喷/d犦明显低于对照组犤(1.80±0.15)分,(1.25±0.14)分,(2.40±0.25)喷/d犦(t=2.5～2.8,P<0.05),第24周明显低于对照组t=10.8～13.0,P(<0.01)。治疗组治疗后第1秒用力呼气量和最大呼气峰速值(peakexpiratoryflowrates,PEFR较对照组明显改善)(t=2.4～14.0,P<0.05～0.01),生活质量较对照组明显提高(t=3.1～8.0,P<0.01)。结论:沙美特罗替卡松干粉剂吸入可改善患者肺功能及提高生活质量。AIM: To observe the interventional effect of Seretide (salmeterol and fluticasone propionate dry powder inhalant) on bronchial asthma, and investigate the influence of Seretide on the lung function and quality of life (QOL) in the patients.METHODS: Sixty four patients with moderate and severe bronchial asthma, who were in accordance with the inclusion criteria and treated in the respiratory clinic of Zhanjiang Central People's Hospital during June 2002 and April 2004, were randomly divided into therapy group (n=32) and control group (n=32). Patients in the therapy group inhaled Seretids twice a day for 24 weeks, while those in the control group inhaled Flixotide twice a day for 24 weeks. The lung function was examined before and 1,4,12 and 24 weeks after treatment, and the QOL was evaluated before and after treatment respectively in both groups.RESULTS: The scores of asthma symptom at day and at night and the dosage of ventolin in the therapy group [1.69± 0.14,1.15± 0.15,(2.23± 0.23) press per day] were obviously lower than those in the control group [1.80± 0.15,1.25± 0.14,(2.40± 0.25) press per day] 1 week after treatment (t=2.5 to 2.8, P< 0.05), those were markedly lower than in the control group 24 weeks after treatment (t=10.8 to 13.0, P< 0.01). Compared with the control group, the forced expiratory volume in the first second (FEV1) and the peak expiratory flow rates (PEFR) after treatment in the therapy group were remarkably improved as compared with those in the control group (t=2.4 to 14.0, P< 0.05 to 0.01), and QOL was also obviously ameliorated (t=3.1 to 8.0, P< 0.01). CONCLUSION: Seretide has better effects in ameliorating the lung function and improving QOL of patients with bronchial asthma than Flixotide.

关 键 词：哮喘/药物疗法 肾上腺素能激动剂/治疗应用 生活质量 呼吸功能试验 

分 类 号：R562.2[医药卫生—呼吸系统]